Tesamorelin for Visceral Fat

Tesamorelin is the one GHRH analog with a real clinical trial backbone for a specific body composition endpoint: reduction of visceral adipose tissue. That's the deep fat — the kind that packs around the liver and organs, that drives metabolic disease, that doesn't move on a regular cut the way subcutaneous fat does.

It's not a general fat-loss peptide. It's a specific tool for a specific problem.

Who this is for

• Someone with visceral adiposity that's out of proportion to overall body fat — the "skinny-fat" pattern, or the lean person with a surprising waist circumference
• Someone with elevated liver enzymes and/or imaging-confirmed fatty liver
• Metabolic-dysfunction presentations: high fasting insulin, high triglycerides, low HDL, waist > 40" (men) / 35" (women)
• Post-GLP-1 users who lost peripheral fat but whose central fat is still disproportionate

This is not the first protocol to reach for if you just want to lose weight. It's for when visceral fat specifically is the target.

The compound

• Tesamorelin — 1-2 mg sub-Q, once daily, pre-bed or pre-breakfast on empty stomach

Run 12-26 weeks. Tesamorelin is unusual among peptides in that the clinical trial data supports longer runs.

Weekly schedule

Day	Pre-bed (or pre-breakfast, fasted)
Mon-Sun	Tesamorelin 1-2 mg sub-Q

No off days. Same time each day. Consistency matters more than the specific time of day.

Why pre-bed (or fasted)

Tesamorelin works by stimulating the pituitary to release endogenous GH. The GH pulse is blunted by circulating glucose and insulin — which is why food within 2 hours of dosing reduces effect.

Pre-bed timing aligns the peptide-induced GH pulse with the natural largest-pulse-of-the-day that occurs in early deep sleep. That's why pre-bed is slightly preferred over morning dosing for most users. But if you can't fast 2 hours before bed, fasted morning works.

Starting dose

Begin at 1 mg daily for the first two weeks. If tolerating well (minimal fluid retention, no carpal tunnel symptoms, no glucose issues), increase to 2 mg daily for the remainder of the cycle.

Some users stay at 1 mg indefinitely — the clinical dose is 2 mg, but the community finds 1 mg effective for the visceral-fat endpoint with fewer side effects.

Why Tesamorelin specifically

GHRH analogs as a class stimulate GH release. What makes Tesamorelin different:

1. It's the only GHRH analog with FDA approval for a visceral-fat indication (HIV-associated lipodystrophy)
2. Multiple RCTs show ~15-20% reduction in visceral adipose tissue over 26 weeks
3. Its half-life and kinetics produce a strong pulse without the sustained receptor engagement that leads to desensitization

CJC-1295 without DAC is mechanically similar but has less specific data on visceral fat as an endpoint. If VAT is the target, Tesamorelin is the right tool.

What to expect

• Week 1-2: Possible mild fluid retention (puffy hands/face) that usually resolves. Vivid dreams. Slightly better sleep quality after a few days of adjustment.
• Week 4-6: Waist circumference begins to drop meaningfully. Body weight may not change much — the fat shift is from visceral to lean compartment.
• Week 8-12: Dramatic changes in fasting lipids often visible on labs. Triglycerides drop. Energy level stabilizes.
• Week 16-26: Full effect. The 15-20% VAT reduction from the clinical literature is typical territory for compliant users.

Cost ballpark

Tesamorelin is expensive. A 2 mg vial runs $30-80 depending on source. At 2 mg/day, a 12-week cycle uses about 84 vials — though most people reconstitute in larger vials that come as 10-20 mg. Expect $400-900 for a 12-week run, higher for 26 weeks.

Compounded Tesamorelin from pharmacies is considerably more ($300-600/month in the US).

Labs worth pulling

Baseline and every 4-6 weeks:

• Fasting glucose, A1c, fasting insulin
• Lipid panel (full, with triglycerides as the key marker)
• IGF-1 (will rise — expect 1.5-2x baseline at working dose)
• Liver enzymes (often improve significantly)

Body composition imaging: DEXA at baseline and 12 weeks if affordable. Waist circumference at the same spot, same time of day, weekly if not.

Red flags — when to stop

• Fasting glucose rising meaningfully (>100 mg/dL when baseline was normal) — this is the most common reason to pause
• Persistent peripheral edema or swelling
• Carpal tunnel symptoms that don't resolve with dose reduction
• IGF-1 above 400 ng/mL on labs — reduce dose
• Any new visual changes — rare but reported with GH-elevating protocols

Combining with other protocols

Tesamorelin + GLP-1 is a powerful pair for someone with both overall weight to lose and disproportionate visceral fat. The GLP-1 handles the peripheral fat and appetite; Tesamorelin handles the central compartment.

Tesamorelin + GH stack (CJC/Ipa) is redundant — you're stimulating the same axis twice. Pick one.

Where to go next

• The GLP-1 fat loss protocol is the natural complement if peripheral fat is also in scope.
• The cutting cycle is broader body-comp territory.
• Pepperpedia Tesamorelin entry has the trial data and mechanism.
• Tesamorelin + Ipamorelin stack on Pepperpedia for the combined GHRH+GHRP variation.
• VAT reduction results, lab changes, and long-run discussions in the Protocol Discussions forum.